How Eli Lilly plans to fix supply snag for blockbuster diabetes drug
Eli Lilly has a dual-track approach to make more of its fast-growing diabetes and obesity drugs.
Source: cnbc.com
Stay updated with breaking news from Research Park Triangle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly has a dual-track approach to make more of its fast-growing diabetes and obesity drugs.
The case for owning Eli Lilly got stronger Thursday, as diabetes drug Mounjaro crossed $1 billion in quarterly sales for the first time.